Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...

And based on the data so far, amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling ...

but still less than what’s been seen with competitor Eli Lilly’s Zepbound. In a 72-week study, a 7.2-milligram dose of Wegovy led patients with obesity to lose 18.7% of their weight ...

And based on the data so far, amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight loss was ...

While her study ... they do lose weight and ovulation resumes, their fertility can come back.” Experts see no signs of the upward trend slowing. In fact, the use of drugs such as Zepbound ...

the study noted. Related FDA approves weight-loss drug Zepbound to treat sleep apnea FDA says shortage of GLP-1 drug tirzepatide is over Merck reaches weight-loss drug deal worth up to $2 billion ...

In the phase 3b STEP UP study, an experimental 7.2-mg semaglutide dose helped patients lose more weight on average at ... Wegovy and Zepbound tipped to fuel $20B boom in heart failure market ...

The newest weight-loss drugs ... The study included people taking different types drugs in this category—semaglutide (Wegovy and Ozempic), and tirzepatide (Mounjaro and Zepbound).

also includes Wegovy and Zepbound. GLP-1s were developed to treat diabetes, but they have become popular weight-loss medications. MORE: In Kensington, outreach workers give out food, clothing and ...